Document is current
Any future updates will be listed below
-
Authors
Xue, Sheng-Li https://orcid.org/0000-0003-4609-616X
Liu, Mei-Jing
Qian, Chong-Sheng https://orcid.org/0000-0002-4237-1825
Chen, Su-Ning
Qiu, Hui-Ying
Kang, Li-Qing
Dai, Hai-Ping https://orcid.org/0000-0003-1125-7744
Gong, Wen-Jie
Chen, Li-Yun
Yao, Zhen
Xu, Ming-Zhu
Zhou, Hai-Xia https://orcid.org/0009-0001-5309-5715
Yang, Xiao-Fei
Wu, Qian https://orcid.org/0009-0009-0254-7302
Dou, Xue-Qing
Zhang, Jian
Liu, Yin
Cui, Qing-Ya https://orcid.org/0000-0002-5067-5650
Li, Zheng
Xu, Yang https://orcid.org/0000-0003-4643-2098
Qiao, Man
Zhang, Tong-Tong
Tan, Jing-Wen
Xu, Nan
Li, Ming-Hao
Yu, Zhou
Lou, Xiao-Yan
Wang, Wei
Zhu, Hong-Jia
Qin, Lu
Yu, Lei
Tang, Xiao-Wen https://orcid.org/0000-0003-1766-7891
Wu, De-Pei https://orcid.org/0000-0002-6312-3863
-
Funding
Funding for this research was provided by:
Unicar-Therapy Ltd
- License Information
-
More Information
Article History
Received: 18 July 2025
Revised: 24 September 2025
Accepted: 13 October 2025
First Online: 27 October 2025
Competing interests
: LY is a founding member of Unicar-Therapy Ltd, a biotechnology company focusing on research and development of tumor cellular immunotherapy. LQK, NX, MHL, ZY, XYL, WW, HJZ, and LQ are employed by Unicar-Therapy Ltd. All other authors declare no competing interests.
: This study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Soochow University and registered with ClinicalTrials.gov (NCT04825496). Written informed consent was obtained from all participants according to the Declaration of Helsinki.
